JP2021521776A5 - - Google Patents
Info
- Publication number
- JP2021521776A5 JP2021521776A5 JP2020556863A JP2020556863A JP2021521776A5 JP 2021521776 A5 JP2021521776 A5 JP 2021521776A5 JP 2020556863 A JP2020556863 A JP 2020556863A JP 2020556863 A JP2020556863 A JP 2020556863A JP 2021521776 A5 JP2021521776 A5 JP 2021521776A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- item
- sequence
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024056106A JP7761293B2 (ja) | 2018-04-19 | 2024-03-29 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862660083P | 2018-04-19 | 2018-04-19 | |
| US62/660,083 | 2018-04-19 | ||
| PCT/US2019/028239 WO2019204683A1 (en) | 2018-04-19 | 2019-04-19 | T cell receptors with mage-b2 specificity and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056106A Division JP7761293B2 (ja) | 2018-04-19 | 2024-03-29 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021521776A JP2021521776A (ja) | 2021-08-30 |
| JP2021521776A5 true JP2021521776A5 (enExample) | 2022-03-03 |
| JP7469807B2 JP7469807B2 (ja) | 2024-04-17 |
Family
ID=68239239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020556863A Active JP7469807B2 (ja) | 2018-04-19 | 2019-04-19 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
| JP2024056106A Active JP7761293B2 (ja) | 2018-04-19 | 2024-03-29 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024056106A Active JP7761293B2 (ja) | 2018-04-19 | 2024-03-29 | Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12202877B2 (enExample) |
| EP (1) | EP3784255B1 (enExample) |
| JP (2) | JP7469807B2 (enExample) |
| KR (1) | KR102892744B1 (enExample) |
| CN (1) | CN112236447B (enExample) |
| CA (1) | CA3097399A1 (enExample) |
| WO (1) | WO2019204683A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| MA49156A (fr) | 2014-12-23 | 2020-03-25 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
| KR20240007775A (ko) | 2016-12-08 | 2024-01-16 | 이매틱스 바이오테크놀로지스 게엠베하 | T 세포 수용체 및 이를 사용하는 면역 요법 |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| US20230405046A1 (en) * | 2020-03-16 | 2023-12-21 | Biontech Cell & Gene Therapies Gmbh | Antigen-specific t cell receptors and t cell epitopes |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| CN111718409B (zh) * | 2020-06-17 | 2021-03-02 | 深圳豪石生物科技有限公司 | 一种t细胞受体及其应用 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| KR20230096110A (ko) * | 2020-11-04 | 2023-06-29 | 페이트 세러퓨틱스, 인코포레이티드 | 고형 종양을 표적화하는 멀티플렉스화된 조작 iPSC 및 면역 효과기 세포 |
| US20250282887A1 (en) * | 2021-04-02 | 2025-09-11 | Amgen Inc. | Mageb2 binding constructs |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| AU2022375782B2 (en) | 2021-10-28 | 2026-02-26 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP7787991B2 (ja) | 2021-10-29 | 2025-12-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| KR20240123836A (ko) | 2021-12-22 | 2024-08-14 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| US12122764B2 (en) | 2021-12-22 | 2024-10-22 | Gilead Sciences, Inc. | IKAROS zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| KR20250028371A (ko) | 2022-07-01 | 2025-02-28 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| AU2023409398A1 (en) | 2022-12-22 | 2025-06-05 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CR20250446A (es) | 2023-04-21 | 2025-12-02 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| AU2024306338A1 (en) | 2023-06-30 | 2026-01-08 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121620513A (zh) | 2023-07-26 | 2026-03-06 | 吉利德科学公司 | Parp7抑制剂 |
| KR20260046403A (ko) | 2023-07-26 | 2026-04-07 | 길리애드 사이언시즈, 인코포레이티드 | Parp7 저해제 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2651174A1 (en) | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| HRP20171164T1 (hr) | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| CN103124740B (zh) | 2010-09-21 | 2015-09-02 | 美国卫生和人力服务部 | 抗-ssx-2t细胞受体和相关材料及使用方法 |
| WO2012054825A1 (en) * | 2010-10-22 | 2012-04-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mage-a3 t cell receptors and related materials and methods of use |
| AU2012309830B2 (en) * | 2011-09-15 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage |
| KR102480188B1 (ko) | 2012-09-14 | 2022-12-21 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체 |
| US11834674B2 (en) | 2014-12-11 | 2023-12-05 | Riken | Modified immunocyte, method for producing modified immunocyte and utilization thereof |
| EP3234130B1 (en) * | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| KR20190059874A (ko) | 2016-04-08 | 2019-05-31 | 어댑티뮨 리미티드 | T 세포 수용체 |
| BR112018070637A2 (pt) * | 2016-04-08 | 2019-02-05 | Adaptimmune Ltd | receptores de células t |
| CN109996868A (zh) | 2016-09-23 | 2019-07-09 | 弗雷德哈钦森癌症研究中心 | 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途 |
| GB201616238D0 (en) | 2016-09-23 | 2016-11-09 | Adaptimmune Ltd | Modified T cells |
| MX2019003768A (es) | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
| AU2018231405B2 (en) * | 2017-03-07 | 2024-02-08 | Universität Basel | MR1 restricted T cell receptors for cancer immunotherapy |
| US20210147550A1 (en) * | 2017-08-18 | 2021-05-20 | Joshua Michael Francis | Antigen-binding proteins targeting shared antigens |
-
2019
- 2019-04-19 WO PCT/US2019/028239 patent/WO2019204683A1/en not_active Ceased
- 2019-04-19 CN CN201980037254.1A patent/CN112236447B/zh active Active
- 2019-04-19 JP JP2020556863A patent/JP7469807B2/ja active Active
- 2019-04-19 CA CA3097399A patent/CA3097399A1/en active Pending
- 2019-04-19 KR KR1020207031165A patent/KR102892744B1/ko active Active
- 2019-04-19 US US17/048,748 patent/US12202877B2/en active Active
- 2019-04-19 EP EP19787925.7A patent/EP3784255B1/en active Active
-
2024
- 2024-03-29 JP JP2024056106A patent/JP7761293B2/ja active Active
- 2024-12-09 US US18/973,614 patent/US20250101079A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021521776A5 (enExample) | ||
| US20250171560A1 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| EP3615565B1 (en) | Tcr and peptides | |
| AU2025205077A1 (en) | Methods for enhancing efficacy of therapeutic immune cells | |
| CN107074970B (zh) | 特异性针对wt-1的t细胞免疫疗法 | |
| US20190119350A1 (en) | Ny-eso-1 specific tcrs and methods of use thereof | |
| SG11202110171QA (en) | Mage a4 t cell receptors | |
| EP3095792A1 (en) | T cell receptor with specificity for myeloperoxidase peptide and uses thereof | |
| RU2018135097A (ru) | Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине | |
| US20210379149A1 (en) | Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy | |
| CA3117272A1 (en) | Tcr and peptides | |
| US11161913B2 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| AU2019324162A1 (en) | Immunotherapy targeting KRAS or Her2 antigens | |
| US20240270813A1 (en) | T CELL RECEPTORS (TCRs) TARGETING MINOR HISTOCOMPATIBILITY ANTIGEN HA-1 | |
| Geiger et al. | New approaches for the immunotherapy of acute myeloid leukemia | |
| CN113195528B (zh) | 对ha-1h特异的结合蛋白及其用途 | |
| JP7558935B2 (ja) | メソテリンを標的とする免疫療法 | |
| JP2022505107A5 (enExample) | ||
| JP2023526416A5 (enExample) | ||
| US20230133564A1 (en) | Cd3-fusion protein and uses thereof | |
| CN113929767A (zh) | 具有高亲和力的t细胞受体及其用途 | |
| JP2022554349A5 (enExample) | ||
| AU2019327490B2 (en) | Chimeric antigen receptor cells for treating solid tumor | |
| US20250289866A1 (en) | Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use | |
| JP2024526836A5 (enExample) |